The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis

Autor: Caroline Seynaeve, E. A. van Vliet, G.J. Liefers, A. Sajet, Esther Bastiaannet, C.C. Engels, Hein Putter, Jms Bartlett, R. L. P. Van Vlierberghe, Vincent T.H.B.M. Smit, A. Charehbili, Peter J. K. Kuppen, C.J.H. van de Velde
Přispěvatelé: Developmental Biology, Clinical Genetics, Medical Oncology
Rok vydání: 2015
Předmět:
Oncology
Cancer Research
medicine.medical_treatment
T-Lymphocytes
Regulatory
chemistry.chemical_compound
Immunophenotyping
Preclinical Study
Breast cancer
Adjuvant endocrine therapy
Exemestane
Aged
80 and over
education.field_of_study
FOXP3
Forkhead Transcription Factors
Middle Aged
Prognosis
Combined Modality Therapy
Postmenopause
Receptors
Estrogen
Chemotherapy
Adjuvant
Female
Adjuvant
medicine.drug
Adult
medicine.medical_specialty
Population
Breast Neoplasms
SDG 3 - Good Health and Well-being
Internal medicine
medicine
Biomarkers
Tumor
Endocrine system
Humans
Tumor immune subtypes
education
Aged
HLA-G Antigens
Prognostic and predictive value
business.industry
Histocompatibility Antigens Class I
medicine.disease
Androstadienes
Tamoxifen
chemistry
Immunology
Neoplasm Recurrence
Local
business
Zdroj: Breast Cancer Research and Treatment, 149(3), 587-596. Springer New York
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, 149(3), 587-596
ISSN: 1573-7217
0167-6806
Popis: Evidence exists for an immunomodulatory effect of endocrine therapy in hormone receptor-positive (HR+ve) breast cancer (BC). Therefore, the aim of this study was to define the prognostic and predictive value of tumor immune markers and the tumor immune profile in HR+ve BC, treated with different endocrine treatment regimens. 2,596 Dutch TEAM patients were treated with 5 years of adjuvant hormonal treatment, randomly assigned to different regimens: 5 years of exemestane or sequential treatment (2.5 years of tamoxifen–2.5 years of exemestane). Immunohistochemistry was performed for HLA class I, HLA-E, HLA-G, and FoxP3. Tumor immune subtypes (IS) (low, intermediate & high immune susceptible) were determined by the effect size of mono-immune markers on relapse rate. Patients on sequential treatment with high level of tumor-infiltrating FoxP3+ cells had significant (p = 0.019, HR 0.729, 95 % CI 0.560–0.949) better OS. Significant interaction for endocrine treatment and FoxP3+ presence was seen (OS p
Databáze: OpenAIRE
Externí odkaz: